Five-year Leqembi follow-up shows signs of slower decline, but long-term benefits still need more rigorous comparison
Among 351 patients with early Alzheimer’s disease who continued treatment, disease progression after five years was lower than in an external follow-up cohort. However, the lack of a concurrent randomized placebo group limits the interpretation of these long-term data.